Insulin-stimulated lipogenesis gets an epigenetic makeover

Area of Science:

• Biochemistry
• Molecular Biology
• Metabolic Diseases

Background:

• Hepatic de novo lipogenesis is a key driver of nonalcoholic fatty liver disease (NAFLD).
• Understanding the molecular mechanisms regulating lipogenesis is crucial for treating metabolic disorders.

Purpose of the Study:

• To identify novel epigenetic regulators of hepatic lipogenesis.
• To elucidate the role of Slug in insulin-mediated lipogenesis and NAFLD pathogenesis.

Main Methods:

• Investigated the role of Slug in regulating lipogenesis using molecular biology techniques.
• Examined the interaction between Slug, insulin signaling, and histone demethylase Lsd1.
• Assessed the therapeutic potential of targeting Slug or Lsd1 in mouse models of obesity-associated NAFLD and insulin resistance.

Main Results:

• Identified Slug as a novel epigenetic regulator of hepatic lipogenesis, stabilized by insulin signaling.
• Demonstrated that Slug recruits Lsd1 to the fatty acid synthase gene promoter, enhancing lipogenesis.
• Showed that genetic deletion or inhibition of Slug or Lsd1 reduces lipogenesis and ameliorates NAFLD and insulin resistance in mice.

Conclusions:

• Slug is a critical mediator of insulin-stimulated hepatic lipogenesis.
• Targeting the Slug-Lsd1 axis offers a potential therapeutic strategy for NAFLD and associated insulin resistance.